These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 33954789)

  • 1. Randomized Controlled Trial Evaluating the Use of Zoledronic Acid in Duchenne Muscular Dystrophy.
    Zacharin M; Lim A; Gryllakis J; Siafarikas A; Jefferies C; Briody J; Heather N; Pitkin J; Emmanuel J; Lee KJ; Wang X; Simm PJ; Munns CF
    J Clin Endocrinol Metab; 2021 Jul; 106(8):2328-2342. PubMed ID: 33954789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment.
    Bianchi ML; Morandi L; Andreucci E; Vai S; Frasunkiewicz J; Cottafava R
    Osteoporos Int; 2011 Feb; 22(2):529-39. PubMed ID: 20458570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal changes in bone mineral density and trabecular bone score following yearly zoledronic acid infusion in postmenopausal osteoporosis-a retrospective-prospective study from southern India.
    Sooragonda B; Cherian KE; Jebasingh FK; Dasgupta R; Asha HS; Kapoor N; Thomas N; Paul TV
    Arch Osteoporos; 2019 Jul; 14(1):79. PubMed ID: 31321603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of combined teriparatide and zoledronic acid on posterior lumbar vertebral fusion in an aged ovariectomized rat model of osteopenia.
    Yishake M; Yasen M; Jiang L; Liu W; Xing R; Chen Q; Lin H; Dong J
    J Orthop Res; 2018 Mar; 36(3):937-944. PubMed ID: 28796280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy.
    Tian C; Wong BL; Hornung L; Khoury JC; Rybalsky I; Shellenbarger KC; Rutter MM
    Neuromuscul Disord; 2020 Jul; 30(7):599-610. PubMed ID: 32680651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study.
    Suthar R; Reddy BVC; Malviya M; Sirari T; Attri SV; Patial A; Tageja M; Didwal G; Khandelwal NK; Saini AG; Saini L; Sahu JK; Dayal D; Sankhyan N
    J Pediatr Endocrinol Metab; 2021 May; 34(5):573-581. PubMed ID: 33838091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy.
    Sbrocchi AM; Rauch F; Jacob P; McCormick A; McMillan HJ; Matzinger MA; Ward LM
    Osteoporos Int; 2012 Nov; 23(11):2703-11. PubMed ID: 22297733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy.
    Phung K; McAdam L; Ma J; McMillan HJ; Jackowski S; Scharke M; Matzinger MA; Shenouda N; Koujok K; Jaremko JL; Smit K; Walker S; Hartigan C; Khan N; Konji VN; MacLeay L; Page M; Sykes E; Robinson ME; Alos N; Cummings EA; Ho J; Sbrocchi AM; Stein R; Saleh D; Craven BC; Dang UJ; Siminoski K; Rauch F; Ward LM
    Osteoporos Int; 2023 Jan; 34(1):147-160. PubMed ID: 36342539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
    Tian C; Wong BL; Hornung L; Khoury JC; Miller L; Bange J; Rybalsky I; Rutter MM
    Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.
    Moretti A; Liguori S; Paoletta M; Gimigliano F; Iolascon G
    Adv Ther; 2022 Jul; 39(7):3308-3315. PubMed ID: 35614293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV.
    Hoy JF; Richardson R; Ebeling PR; Rojas J; Pocock N; Kerr SJ; Martinez E; Carr A;
    AIDS; 2018 Sep; 32(14):1967-1975. PubMed ID: 29927785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Bisphosphonates on Osteoporosis Induced by Duchenne Muscular Dystrophy: A Prospective Study.
    Zheng WB; Dai Y; Hu J; Zhao DC; Wang O; Jiang Y; Xia WB; Xing XP; Li M
    Endocr Pract; 2020 Dec; 26(12):1477-1485. PubMed ID: 33471740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates.
    Catalano A; Vita GL; Bellone F; Sframeli M; Distefano MG; La Rosa M; Gaudio A; Vita G; Morabito N; Messina S
    J Endocrinol Invest; 2022 Mar; 45(3):517-525. PubMed ID: 34524678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
    van Bodegraven AA; Bravenboer N; Witte BI; Dijkstra G; van der Woude CJ; Stokkers PC; Russel MG; Oldenburg B; Pierik M; Roos JC; van Hogezand RA; Dik VK; Oostlander AE; Netelenbos JC; van de Langerijt L; Hommes DW; Lips P;
    Gut; 2014 Sep; 63(9):1424-30. PubMed ID: 24146170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone Mineral Density Assessment by Quantitative Computed Tomography in Glucocorticoid-Treated Boys With Duchenne Muscular Dystrophy: A Linear Mixed-Effects Modeling Approach.
    Liu C; Yang DD; Zhang L; Lei XG; Jia FL; Liao Y; Chen XJ; Ning G; Luo W; Qu HB
    Front Endocrinol (Lausanne); 2022; 13():860413. PubMed ID: 35399923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis.
    Koldkjær Sølling AS; Harsløf T; Langdahl B
    Osteoporos Int; 2019 May; 30(5):995-1002. PubMed ID: 30656367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
    Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in β-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy.
    Darvishi-Khezri H; Kosaryan M; Akbarzadeh R; Aliasgharian A; Fazli M
    Med Arch; 2018 Jun; 72(3):170-173. PubMed ID: 30061760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced bone mineral density in adolescents with Duchenne Muscular Dystrophy (DMD) and scoliosis.
    Tsaknakis K; Jäckle K; Lüders KA; Lorenz HM; Braunschweig L; Hell AK
    Osteoporos Int; 2022 Sep; 33(9):2011-2018. PubMed ID: 35583603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.
    Pavón de Paz I; Rosado Sierra JA; Pérez Blanco C; Modroño Móstoles N; Guijarro de Armas G; Navea Aguilera C
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Feb; 66(2):108-116. PubMed ID: 30077631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.